Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Shares Outstanding (2016 - 2025)

China Pharma Holdings filings provide 16 years of Shares Outstanding readings, the most recent being $15.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 375.86% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.5 million, a 375.86% increase, with the full-year FY2025 number at $15.5 million, up 375.86% from a year prior.
  • Shares Outstanding hit $15.5 million in Q4 2025 for China Pharma Holdings, up from $5.0 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $45.6 million in Q2 2021 to a low of $946791.0 in Q4 2021.
  • Median Shares Outstanding over the past 5 years was $3.3 million (2024), compared with a mean of $7.0 million.
  • Biggest five-year swings in Shares Outstanding: crashed 89.18% in 2022 and later soared 375.86% in 2025.
  • China Pharma Holdings' Shares Outstanding stood at $946791.0 in 2021, then surged by 420.81% to $4.9 million in 2022, then soared by 115.48% to $10.6 million in 2023, then crashed by 69.3% to $3.3 million in 2024, then surged by 375.86% to $15.5 million in 2025.
  • The last three reported values for Shares Outstanding were $15.5 million (Q4 2025), $5.0 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.